AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2149655 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1168
Study 6248010 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0
Study 6248010 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 0
Study 6248010 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 31846600 — intervention group
Group type: EXPERIMENTAL
Intervention: Running red lights (always vs. never)
Number of subjects: 0
Study 31846600 — intervention group
Group type: EXPERIMENTAL
Intervention: Riding after drinking (yes vs. no)
Number of subjects: 0
Study 31846600 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying adults while riding (always vs. never)
Number of subjects: 0
Study 31846600 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning without signaling (sometimes vs. never)
Number of subjects: 0
Study 31846600 — intervention group
Group type: EXPERIMENTAL
Intervention: Riding in the motor vehicle lane (always vs. never)
Number of subjects: 0
Study 31846600 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior crash history (yes vs. no)
Number of subjects: 0
Study 31846600 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of e-bikes (scooter-style e-bikes vs. bicycle-style e-bikes)
Number of subjects: 0
Study 29653532 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-help intervention for psychosis, duration of 8 weeks, includes modules on delusion, voice hearing, social competence, mindfulness, and others.
Number of subjects: 0
Study 29653532 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group, duration of 8 weeks.
Number of subjects: 0
Study 28805177 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish protein isolate (FPi) diet
Number of subjects: 441
Study 28805177 — intervention group
Group type: COMPARATOR
Intervention: Standard diet without FPi
Number of subjects: 441
Study 26323291 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (two cigarettes)
Number of subjects: 0
Study 26323291 — intervention group
Group type: COMPARATOR
Intervention: Control (30-min waiting period)
Number of subjects: 0
Study 24088993 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline (HS)
Number of subjects: 83
Study 24088993 — intervention group
Group type: EXPERIMENTAL
Intervention: HS + 6% dextran‐70 (HSD)
Number of subjects: 83
Study 24088993 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 83
Study 24088993 — intervention group
Group type: EXPERIMENTAL
Intervention: HS
Number of subjects: 83
Study 24088993 — intervention group
Group type: EXPERIMENTAL
Intervention: HSD
Number of subjects: 83
Study 24088993 — intervention group
Group type: EXPERIMENTAL
Intervention: HS, HSD
Number of subjects: 83
Study 21958068 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 75
Study 21958068 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan 80 mg
Number of subjects: 75
Study 21958068 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg plus Telmisartan 80 mg
Number of subjects: 75
Study 17996211 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep lamellar endothelial keratoplasty (DLEK)
Number of subjects: 27
Study 17996211 — intervention group
Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PK)
Number of subjects: 27
Study 16860426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 vaginal gel (52.5mg, 3.5%)
Number of subjects: 0
Study 16860426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12840628 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately active participants (4.5-7.4 weight-bearing h.d-1)
Number of subjects: 400
Study 12840628 — intervention group
Group type: EXPERIMENTAL
Intervention: Most active participants (>=7.5 weight-bearing h.d-1)
Number of subjects: 400
Study 10963811 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch-pollen immunotherapy (IT)
Number of subjects: 25
Study 10963811 — intervention group
Group type: COMPARATOR
Intervention: Birch-pollen extract (BPE)
Number of subjects: 25
Study 10963811 — intervention group
Group type: COMPARATOR
Intervention: Tetanus toxoid (TT)
Number of subjects: 25
Study 8985103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold packs (Cryogel, 8-12 degrees C)
Number of subjects: 12
Study 8985103 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot packs (Parafango, 50-60 degrees C)
Number of subjects: 12
Study 1728157 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 27
Study 1728157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 27
Study 6371879 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (TZD)
Number of subjects: 0
Study 6371879 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMT)
Number of subjects: 0
Study 6371879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31335194 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg
Number of subjects: 1362
Study 31335194 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 1362
Study 31335194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1362
Study 29352823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Number of subjects: 56
Study 29352823 — intervention group
Group type: COMPARATOR
Intervention: Computer Game (CG)
Number of subjects: 56
Study 26628552 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred bedside rounds (PCBR)
Number of subjects: 236
Study 26628552 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PCBR)
Number of subjects: 236
Study 25319597 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention for DVA survivors
Number of subjects: 260
Study 25319597 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 260
Study 23243245 — intervention group
Group type: COMPARATOR
Intervention: AMP processed to particle size of 300 mum
Number of subjects: 120
Study 23243245 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP processed to particle size of 149 mum
Number of subjects: 120
Study 23243245 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP processed to particle size of 75 mum
Number of subjects: 120
Study 23243245 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP processed to particle size of 37 mum
Number of subjects: 120
Study 23243245 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP (5 g/kg of diet)
Number of subjects: 120
Study 23243245 — intervention group
Group type: COMPARATOR
Intervention: Basal diet only (control)
Number of subjects: 120
Study 21308291 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival instrumentation with ultrasonic device using PVP-I (10%) as cooling liquid
Number of subjects: 32
Study 21308291 — intervention group
Group type: COMPARATOR
Intervention: Identical treatment using distilled water as cooling liquid
Number of subjects: 32
Study 17714828 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid ingestion of a large glucose beverage consumed with breakfast and lunch
Number of subjects: 14
Study 17714828 — intervention group
Group type: COMPARATOR
Intervention: Slow ingestion of the same volume of glucose beverage consumed in eight portions
Number of subjects: 14
Study 16368799 — intervention group
Group type: EXPERIMENTAL
Intervention: epoprostenol (3 ng x kg(‐1) x min(‐1))
Number of subjects: 18
Study 16368799 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 14564686 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/d
Number of subjects: 14
Study 14564686 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/d and MPA 2.5 mg/d
Number of subjects: 14
Study 14564686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11697754 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 28
Study 11697754 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 28
Study 11697754 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (dosage not specified)
Number of subjects: 28
Study 9395691 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Enermed device (magnetically active)
Number of subjects: 30
Study 9395691 — intervention group
Group type: COMPARATOR
Intervention: Placebo device (magnetically inactive)
Number of subjects: 30
Study 7910272 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair (group L) with transabdominal stapling of preperitoneal Prolene mesh.
Number of subjects: 150
Study 7910272 — intervention group
Group type: COMPARATOR
Intervention: Open hernia repair (group O) with tension-free nylon darn.
Number of subjects: 150
Study 2853528 — intervention group
Group type: EXPERIMENTAL
Intervention: minus lenses with full correction for distant vision only
Number of subjects: 240
Study 2853528 — intervention group
Group type: EXPERIMENTAL
Intervention: bifocal lenses
Number of subjects: 240
Study 2853528 — intervention group
Group type: COMPARATOR
Intervention: minus lenses with full correction for continuous use (Reference group)
Number of subjects: 240
Study 31468553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostering Healthy Futures (FHF) program
Number of subjects: 426
Study 31468553 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 426
Study 29141079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin (125 μg, single intravitreal injection)
Number of subjects: 220
Study 29141079 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 220
Study 25957056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lysine acetylsalicylate (LA) 450 mg plus oral prasugrel 60 mg
Number of subjects: 30
Study 25957056 — intervention group
Group type: COMPARATOR
Intervention: Oral aspirin 300 mg plus prasugrel 60 mg
Number of subjects: 30
Study 22167660 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness Recovery Action Planning (WRAP)
Number of subjects: 0
Study 22167660 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 21597295 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated plasma homocysteine levels
Number of subjects: 0
Study 21597295 — intervention group
Group type: COMPARATOR
Intervention: Normal plasma homocysteine levels (control group implied)
Number of subjects: 0
Study 19567309 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental buccal and lingual infiltrations of 2% lidocaine with 1:200,000 epinephrine
Number of subjects: 84
Study 19567309 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental buccal and lingual infiltrations of 4% articaine with 1:200,000 epinephrine
Number of subjects: 84
Study 19567309 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplemental infiltrations)
Number of subjects: 84
Study 19567309 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between 4% articaine and 2% lidocaine
Number of subjects: 84
Study 16776681 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level lipopolysaccharide (LPS) 2 microg
Number of subjects: 19
Study 16776681 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 19
Study 15517755 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M Cavilon No Sting Barrier Film (Cavilon NSBF)
Number of subjects: 40
Study 15517755 — intervention group
Group type: COMPARATOR
Intervention: Zinc oxide oil
Number of subjects: 40
Study 11429350 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 0
Study 11429350 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 0
Study 11429350 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia
Number of subjects: 0
Study 11429350 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual sedation
Number of subjects: 0
Study 9256139 — intervention group
Group type: EXPERIMENTAL
Intervention: CTVP (cyclophosphamide 750 mg/m2, teniposide 75 mg/m2, prednisone 40 mg/m2/d for 5 days plus pirarubicin 50 mg/m2)
Number of subjects: 453
Study 9256139 — intervention group
Group type: COMPARATOR
Intervention: CVP (cyclophosphamide 750 mg/m2, teniposide 75 mg/m2, prednisone 40 mg/m2/d for 5 days)
Number of subjects: 453
Study 9256139 — intervention group
Group type: EXPERIMENTAL
Intervention: CTVP
Number of subjects: 453
Study 9256139 — intervention group
Group type: COMPARATOR
Intervention: CVP
Number of subjects: 453
Study 8016565 — intervention group
Group type: EXPERIMENTAL
Intervention: Predeposit autologous blood transfusion
Number of subjects: 0
Study 8016565 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic blood transfusion
Number of subjects: 0
Study 8016565 — intervention group
Group type: COMPARATOR
Intervention: Untransfused patients
Number of subjects: 0
Study 8016565 — intervention group
Group type: COMPARATOR
Intervention: Transfused with allogeneic blood
Number of subjects: 0
Study 8016565 — intervention group
Group type: COMPARATOR
Intervention: Transfused with autologous blood
Number of subjects: 0
Study 8016565 — intervention group
Group type: COMPARATOR
Intervention: Transfused with both types of blood
Number of subjects: 0
Study 30279573 — intervention group
Group type: COMPARATOR
Intervention: miRs (specifically miRs-374b, -454, -142-3p, -191, -424, -590-3p, -29c, and -15b)
Number of subjects: 36
Study 30392575 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 daily capsules of 200 mg DHA each (n=176)
Number of subjects: 345
Study 30392575 — intervention group
Group type: COMPARATOR
Intervention: 3 daily capsules of vegetable oil without DHA (n=169)
Number of subjects: 345
Study 27109816 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafine glycopyrronium bromide (GB) 12.5, 25 or 50 μg twice daily (BID) plus beclometasone dipropionate plus formoterol fumarate (BDP/FF)
Number of subjects: 178
Study 27109816 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafine glycopyrronium bromide (GB) 25 μg BID plus beclometasone dipropionate plus formoterol fumarate (BDP/FF)
Number of subjects: 178
Study 27109816 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafine glycopyrronium bromide (GB) 50 μg BID plus beclometasone dipropionate plus formoterol fumarate (BDP/FF)
Number of subjects: 178
Study 27109816 — intervention group
Group type: COMPARATOR
Intervention: Beclometasone dipropionate plus formoterol fumarate (BDP/FF) alone
Number of subjects: 178
Study 27109816 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafine glycopyrronium bromide (GB) 12.5 μg BID
Number of subjects: 178
Study 27109816 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafine glycopyrronium bromide (GB) 25 μg BID
Number of subjects: 178
Study 27109816 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafine glycopyrronium bromide (GB) 50 μg BID
Number of subjects: 178
Study 24495365 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS appointment reminders (present)
Number of subjects: 140
Study 24495365 — intervention group
Group type: COMPARATOR
Intervention: No SMS appointment reminders (absent)
Number of subjects: 140
Study 22215473 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose RCHOP chemotherapy (375 mg/m² rituximab, 600 mg/m² cyclophosphamide, 30 mg/m² doxorubicin, 1 mg vincristine, and 40 mg prednisone)
Number of subjects: 85
Study 22215473 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose RCHOP chemotherapy
Number of subjects: 85
Study 20521870 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) initiated at 10 mg/day for opioid-naive patients and equianalgesic dose for opioid-experienced patients.
Number of subjects: 575
Study 20521870 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) titration in patients aged <65 years.
Number of subjects: 575
Study 20521870 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) titration in patients aged >=65 years.
Number of subjects: 575
Study 20521870 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) titration in oxycodone-experienced patients.
Number of subjects: 575
Study 20521870 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) titration in hydrocodone-experienced patients.
Number of subjects: 575
Study 20521870 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful titration of oxymorphone ER regardless of prior opioid therapy, sex, or age.
Number of subjects: 575
Study 18208828 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 15
Study 18208828 — intervention group
Group type: COMPARATOR
Intervention: Low-dose warfarin
Number of subjects: 15
Study 18208828 — intervention group
Group type: COMPARATOR
Intervention: Low-dose warfarin with aspirin
Number of subjects: 15
Study 16135834 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg, single intravenous infusion)
Number of subjects: 347
Study 16135834 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (30 mg per day for 60 days)
Number of subjects: 347
Study 11812681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (2 mg/kg)
Number of subjects: 20
Study 11812681 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.2% (2 mg/kg)
Number of subjects: 20
Study 10418698 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-depleting (T-) amino acid mixture
Number of subjects: 28
Study 10418698 — intervention group
Group type: EXPERIMENTAL
Intervention: D,L-fenfluramine hydrochloride (60 mg) after T-
Number of subjects: 28
Study 10418698 — intervention group
Group type: COMPARATOR
Intervention: Nutritionally balanced (B) amino acid mixture containing tryptophan
Number of subjects: 28
Study 7572689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 559
Study 2115538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 456
Study 2115538 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 456
Study 2115538 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued smoking
Number of subjects: 456
Study 2115538 — intervention group
Group type: COMPARATOR
Intervention: Conservative management after thrombolysis
Number of subjects: 456
Study 7428409 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release aminophylline plus routine inhaled salbutamol
Number of subjects: 11
Study 7428409 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release aminophylline and inhaled salbutamol on demand
Number of subjects: 11
Study 7428409 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release aminophylline plus inhaled salbutamol on need
Number of subjects: 11
Study 7428409 — intervention group
Group type: COMPARATOR
Intervention: Oral salbutamol plus routinely inhaled salbutamol
Number of subjects: 11
Study 31032979 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills 4 Life program (Social Emotional Learning program)
Number of subjects: 66
Study 30080997 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT) screening
Number of subjects: 143
Study 30080997 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval detection
Number of subjects: 143
Study 30080997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonscreened/postscreening
Number of subjects: 143
Study 30080997 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen detected SCLC
Number of subjects: 143
Study 30080997 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval detected SCLC
Number of subjects: 143
Study 30080997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonscreened/postscreening SCLC
Number of subjects: 143
Study 30080997 — intervention group
Group type: COMPARATOR
Intervention: NSCLC cases
Number of subjects: 143
Study 30080997 — intervention group
Group type: EXPERIMENTAL
Intervention: LDCT imaging
Number of subjects: 143
Study 27372902 — intervention group
Group type: EXPERIMENTAL
Intervention: Alertness training
Number of subjects: 0
Study 27372902 — intervention group
Group type: COMPARATOR
Intervention: Active control (AC) training
Number of subjects: 0
Study 25025610 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 10804
Study 25025610 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10804
Study 22372405 — intervention group
Group type: COMPARATOR
Intervention: Red wine and grape juice extracts (WGM) for 4 days
Number of subjects: 0
Study 20588072 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 21
Study 20588072 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 21
Study 17199887 — intervention group
Group type: EXPERIMENTAL
Intervention: standard follow-up
Number of subjects: 320
Study 17199887 — intervention group
Group type: EXPERIMENTAL
Intervention: nurse-led telephone follow-up
Number of subjects: 320
Study 17199887 — intervention group
Group type: EXPERIMENTAL
Intervention: arm 1 with the educational group programme
Number of subjects: 320
Study 17199887 — intervention group
Group type: EXPERIMENTAL
Intervention: arm 2 with the educational group programme
Number of subjects: 320
Study 16373217 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-methods evaluation of a rehabilitation scheme
Number of subjects: 6
Study 16373217 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trial (RCT)
Number of subjects: 6
Study 16373217 — intervention group
Group type: COMPARATOR
Intervention: Ethnographic study
Number of subjects: 6
Study 11943957 — intervention group
Group type: EXPERIMENTAL
Intervention: Dioctahedral smectite combined with hypotonic oral rehydration solution (Gastrolit)
Number of subjects: 54
Study 11943957 — intervention group
Group type: COMPARATOR
Intervention: Gastrolit alone (control group)
Number of subjects: 54
Study 10848048 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 600
Study 10848048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 7791156 — intervention group
Group type: EXPERIMENTAL
Intervention: Criticism of the spouse
Number of subjects: 229
Study 7791156 — intervention group
Group type: EXPERIMENTAL
Intervention: Low number of friends
Number of subjects: 229
Study 7791156 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level of potential support
Number of subjects: 229
Study 2198696 — intervention group
Group type: EXPERIMENTAL
Intervention: Norcolut
Number of subjects: 434
Study 832652 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 10